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aripiprazole in acutely agitated patients
with schizophrenia or bipolar disorder
L. San1*, G. Estrada2, N. Oudovenko2 and E. Vieta3
Abstract
Background: The management of acute agitation manifesting in patients with schizophrenia or bipolar disorder
requires swift pharmacological intervention to provide rapid symptomatic relief and prevent escalation to aggression
and violence. Antipsychotic medications are widely used in this setting and the availability of an inhaled formulation
with deep lung absorption of the antipsychotic loxapine has the potential to deliver a faster onset of therapeutic effect
than the available intramuscular formulations of antipsychotics.
Methods: The efficacy of inhaled loxapine and the alternative antipsychotic aripiprazole delivered via intramuscular
(IM) injection will be compared in the Phase IIIb PLACID study. Adults (18–65 years) with a confirmed diagnosis of
schizophrenia or bipolar I disorder presenting with acute agitation will be randomly assigned to open-label treatment
in a 1:1 ratio. Clinical evaluation will be conducted by raters blinded to treatment assignment. The primary efficacy
endpoint is time to response (defined as a Clinical Global Impression of Improvement [CGI-I] score of 1 [very much
improved] or 2 [much improved]).
Secondary endpoints will include the percentage of responders at different time points after dosing; the proportion of
patients who receive 1 or 2 doses of study drug; time to second dose; time to rescue medication; satisfaction with
study drug (evaluated using Item 14 of the Treatment Satisfaction Questionnaire for Medication); and safety and
tolerability. Approximately 360 patients will be recruited with an interim analysis conducted once 180 patients have
completed the study to decide whether to stop for futility or continue with or without an increase in the sample size
up to additional 288 patients.
Discussion: The PLACID trial will assess the efficacy and safety of inhaled loxapine with deep lung absorption
compared with the IM antipsychotic, aripiprazole, in acutely agitated patients with schizophrenia or bipolar disorder. In
the event that the median time to response of inhaled loxapine is significantly shorter than that of the intramuscular
aripiprazole, the PLACID study has the potential to support the inhaled antipsychotic therapy as the standard of care in
this setting.
Trial registration: The study protocol was registered with the European Clinical Trials Database on the 31 October
2014 (EudraCT number 2014–000456-29).
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Background
Schizophrenia and bipolar disorder are estimated to
affect 21 million and 60 million individuals worldwide,
respectively [1]. Agitation, defined as a state of cognitive
and motor hyperactivity characterized by excessive or in-
appropriate motor or verbal activity with an emotional
arousal element, is common among patients with schizo-
phrenia or bipolar disorder [2–4]. For these patients, the
manifestation of acute agitation represents a serious,
disruptive and morbid complication that can escalate
rapidly and unpredictably from distress to loss of control
and physical aggression and violence towards them-
selves, other patients and their carers [4–6].
Acute agitation is frequently encountered in both
medical and psychiatric emergency settings and should
be managed initially with verbal de-escalation and envir-
onmental management [7, 8]. Continued escalation of
agitation may ultimately require physical restraint and
pharmacological treatment [7, 8]. However, such coer-
cive management measures may damage the therapeutic
relationship between patients and their carer’s and evoke
feelings of panic, fear, powerlessness, anger, frustration,
and injustice [2]. The consequence of this negative asso-
ciation of feelings may destroy trust and lead to patient
reluctance to seek psychiatric care [3]. Early intervention
for acute agitation with a medication delivered via a
non-traumatic route has the potential to avoid the nega-
tive feelings evoked by a traumatic therapeutic encoun-
ter and reinforce the partnership between patient and
their carer [2, 3].
The costs associated with agitation, especially agitation
that escalates to aggression and violence, among patients
with psychiatric disorders may also be considerable al-
though precise estimates of the overall burden are lack-
ing. When inadequately managed, agitation among
psychiatric patients can result in an increase in the num-
ber and duration of inpatient hospital stays, a reduced
likelihood of discharge to community and use of coer-
cive measures and/or escalation to patient violence, pre-
senting a substantial economic burden to the healthcare
system [8, 9]. In Spain, the annual cost of psychiatric
mechanical restraint has been estimated at €27 million
[9]. A separate study conducted in the UK, estimated
that the annual cost per psychiatric ward for contain-
ment was €267,069 in 2014 [10].
Agitation among patients with psychiatric disorders
requires early recognition and swift intervention with
treatments that can achieve rapid symptom relief and
avoid the progression of agitation to aggression and vio-
lence [7]. The acute treatment of agitation associated
with schizophrenia or bipolar disorder includes pharma-
cological tranquilization with oral antipsychotic agents
given alone or in combination with benzodiazepines
[11–13]. However, while a preferred route of delivery in
terms of maintaining a non-traumatic experience for the
patient, orally dosed agents may not be optimal in terms
of delivering a sufficiently rapid onset of therapeutic ef-
fect. Intramuscular (IM) formulations have been shown
to provide relatively faster symptomatic relief compared
with oral formulation of antipsychotics but have the dis-
advantage of a potentially traumatic experience for the
patient [2, 14].
Inhaled loxapine with deep lung absorption is the first
anti-agitation medication available to provide rapid
control of agitation combined with a noncoercive non-
invasive route of administration. It is administered by
inhalation using the Staccato delivery system. The effi-
cacy of inhaled loxapine for the management of agitation
among patients with schizophrenia or bipolar I disorder
has been confirmed in placebo-controlled, Phase III
trials [15–17] and is supported by indirect comparisons
with other antipsychotics [18]. However, head-to-head
comparisons with other antipsychotics, including those
delivered via IM injection, are lacking. Head-to-head
trials, often neglected by regulatory authorities and in-
dustry sponsors, are important for clinical practice [19].
The PLACID study will compare inhaled loxapine and
IM aripiprazole (considered a standard of care in this
setting; [20]) for the prompt stabilization of acutely
agitated patients with schizophrenia or bipolar disorder.
Methods
The PLACID study will evaluate the efficacy, defined as
time to response (Clinical Global Impression of
Improvement [CGI-I] or 1 or 2) of inhaled loxapine as
compared with aripiprazole administered via IM injec-
tion in acutely agitated patients with schizophrenia or
bipolar disorder.
Inhaled loxapine is available in 10 mg dose, being the
delivered dose 9,1 mg, a maximum of 2 doses can be ad-
ministered during 24 h (24). For IM aripiprazole the
standard dose is 9,75 mg with a possibility of two
additional doses during 24 h (14). In this study a max-
imum of 2 doses of both study drugs are allowed [14, 21].
The study will be conducted at up to 30 centres across
Europe including centres in the Czech Republic,
Germany, Russia and Spain and will include male and fe-
male patients aged between 18 and 65 years with a con-
firmed diagnosis of schizophrenia or bipolar I disorder
according to Diagnostic and Statistical Manual of Mental
Disorders (DSM-5) criteria.
Design
The PLACID study is a Phase IIIb, open-label, rater
blind, randomised, active control, prospective, parallel
group, multicentre clinical trial (Fig. 1, Table 1). The
study will be conducted in two phases. The first phase
will enrol approximately 180 patients who will be
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randomly assigned (in a 1:1 ratio) to open-label treat-
ment. Clinical evaluation will be carried out by
personnel blinded to treatment assignment. Patients will
be instructed not to tell the blinded assessor which treat-
ment they received.
An interim analysis will be performed on the phase 1
data to determine whether to continue into phase 2 or
to stop the trial due to futility or unfeasibility. The final
sample size of the PLACID study will be re-calculated
based on the interim analysis results. The two-phase de-
sign with interim analysis is justified due to the limited
availability of CGI-I data during the first 2 h’ post-
administration both for inhaled loxapine and IM aripi-
prazole, and therefore making difficult the sample size
estimation. Data demonstrating meaningful improve-
ments from baseline on the CGI-I scale at 120 mins post
dose are available [15, 16, 20, 22] for both treatments,
but data demonstrating the time course of these im-
provements during the first two hours of treatment,
when rapid and effective action is required to minimise
the risks associated with acute agitation, are lacking.
Patients
The study population will consist of patients meeting
DSM-5 criteria for schizophrenia or bipolar I disorder
experiencing an acute episode of agitation, both hos-
pitalized and attending to a psychiatric or general
emergency room.
To be eligible to participate patients must be clinically
agitated at baseline with a value ≥4 for the Clinical
Global Impression of Severity (CGI-S; [23]) scale and
otherwise in good health. Patients will be specifically ex-
cluded from participation if their agitation is judged to
be caused primarily by acute alcohol or drug intoxica-
tion/withdrawal. Those patients judged to be at serious
risk for suicide will also be excluded. Patients treated
with benzodiazepines or other hypnotics or oral or
short-acting IM antipsychotics within 1 h prior to study
drug administration will be excluded although those pa-
tients may be subsequently reassessed for inclusion.
Other exclusion criteria will include pregnancy or
breastfeeding, a history of or current significant hepatic,
renal, gastroenterologic, respiratory, cardiovascular, en-
docrinologic, neurologic or haematologic disease as well
as acute or active airways disease.
All patients will be required to provide written
informed consent prior to undergoing any study procedure.
Patients considered by appropriately qualified staff to
be of impaired capacity to provide informed consent
will not be eligible for participation. In Spain a proxy or
deferred informed consent is possible. If patients have
recovered the capacity, they will be asked to provide
the informed consent; otherwise the data will not be
used in the analysis.
Study treatments
Baseline evaluations will be performed as close as
possible to, and within 30 min before, administration of
initial study medication. Patients will be randomly
assigned to receive either inhaled loxapine 10 mg
(delivered dose 9.1 mg) using the hand-held, portable,
Staccato delivery system or IM aripiprazole 9.75 mg per
Fig. 1 Study design
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1.3 mL dose. Patients will receive a maximum of 2 doses
of either study drug with the second dose given if
required at least 2 h after the first dose.
Randomisation will be achieved using an interactive
voice response system and will be stratified according to
the patient’s disease type (schizophrenia or bipolar I
disorder).
The planned duration of participation in the study will
be up to approximately 30 h consisting of a screening
and baseline phase of up to 4.5 h and a post-treatment
period which will commence with the administration of
the first dose of study drug and will continue for at least
4 h and up to a maximum of 24 h.
Outcomes and endpoints
The primary efficacy endpoint is time to response mea-
sured during the first 2 h after the first dose. Response is
defined as a CGI-I score of 1 (very much improved) or 2
(much improved). Secondary endpoints will include: the
proportion of patients achieving response at 10, 20, 30,
50, 60, 90 and 120 min after the first dose of study drug;
the total number of patients who receive 1 or 2 doses of
study drug without rescue medication by 4 h and 24 h
after the first dose of study drug; time to rescue medica-
tion; time to the second dose of study drug; and satisfac-
tion with study drug (evaluated using Item 14 of the
Treatment Satisfaction Questionnaire for Medication
[TSQM]; [24]). Safety and tolerability will also be
assessed through the reporting of adverse events,
physical examination, recording of vital signs.
Statistical analysis
The primary endpoint “time to response” is defined as
the first time point in minutes after Dose 1 at which
CGI-I score of 1 or 2 is achieved during the 120 min
after the first dose. The comparison of time to response
between the two treatment groups will be performed
using a Wilcoxon rank-sum test with a two-sided signifi-
cance level of 0.05. Patients without response within 2 h
will be considered as non-responders and the ‘time to
response’ as 4 h (2 h more than the maximum follow-up
for this variable). The median difference (95% CI) will be
estimated by means of the Hodges-Lehmann approach
based on the Wilcoxon rank-sum (Mann-Whitney) dis-
tribution. Kaplan-Meier curves of time to response will
also be presented by treatment group. Additionally, the
Mantel-Haenszel log-rank test will also be conducted for
sensitivity purposes.
Secondary analyses will be exploratory without formal
sample size estimation. Safety and tolerability data will
be presented descriptively.
A total sample size of 180 in each group will have ap-
proximately 90% power to demonstrate superiority of in-
haled loxapine versus IM aripiprazole for the primary
efficacy endpoint at a one-sided significance level of
0.025. If the interim analysis suggests that more than
30% additional patients are required at 0.025 one-tailed
alpha level and approximately 90% power, it will be
considered if it is feasible to include >30% additional
patients. Since there will be neither stopping for over-
whelming efficacy, nor is there a situation where the
sample size will decrease based on the interim analysis
results, the alpha level will be preserved.
Discussion
Acute agitation in patients with psychiatric disorders in-
cluding schizophrenia and bipolar disorder is a serious
complication with the potential to escalate rapidly to ag-
gression and physical violence [3, 5, 6]. Early recognition
of the onset of acute agitation and intervention to rap-
idly calm the agitated patient without over-sedation are
the main goals of the pharmacological management of
such patients [3]. Antipsychotic medications are widely
used in this setting and IM delivery provides a more
rapid onset of effect compared with oral formulations.
However, IM delivery of medication in this setting may
not be optimal for patients already in an agitated state
and may interfere with the therapeutic relationship be-
tween the patient and their carers [2]. Inhaled formula-
tions have the potential to provide a more rapid onset of
effect than IM injection. The medication is delivered
through the lung with rapid transition to the systemic
circulation via a non-coercive, non-invasive route of ad-
ministration [3, 25]. Clinical evaluation of the inhaled
antipsychotic loxapine has demonstrated an onset of
therapeutic effect as early as 10 min after dosing, an ef-
fect that is maintained through 24 h among patients
with acute agitation and schizophrenia or bipolar dis-
order [15, 16, 21, 26].
The PLACID trial will assess the efficacy and safety of
inhaled loxapine compared with the IM antipsychotic,
aripiprazole, in acutely agitated patients with schizophre-
nia or bipolar disorder. The PLACID trial is planned as
a pragmatic trial close to the real world setting.
The CGI scale, which was developed as a brief, stand-
alone assessment of the patient’s global functioning prior
to and after initiating a study medication, will be used to
assess the primary endpoint. This is a simple instrument
widely used in a clinical practice and can be completed
in less than a minute by an experienced rater [27] Even
if not validated for agitation assessment, it was shown
that there is a very good correlation between the CGI
and PANSS-EC [28]. All raters will be trained in the
proper CGI use to assess the agitation grade.
Both inhaled loxapine and IM aripiprazole are cur-
rently available in Europe for the treatment of acute agi-
tation in patients with schizophrenia or bipolar disorder.
San et al. BMC Psychiatry  (2017) 17:126 Page 5 of 7
REMS (Risk Evaluation and Mitigation Strategy) is
necessary with inhaled loxapine to mitigate the risk of
bronchospasm. For this reason, only the centers with im-
mediate access on site to supplies and personnel trained to
manage acute bronchospasm will participate in this study.
REMS is the strategy to manage a known or potential
serious risk associated with a drug or biological product
required by the US FDA (Food and Drug Administration).
The pharmacokinetic profiles (PK) of both drugs differ
significantly and this is explained by the differences in
the administration route. The peak plasma concentration
of IM aripiprazole is achieved at 1 h, while for inhaled
loxapine it is 2–3 min. Such a short time is explained by
the fact that inhaled loxapine is directly absorbed into
the blood stream with a PK profile similar to IV formu-
lations. This study will prove if these differences in PK
parameters correspond to clinical parameters, namely
shorter time to response of inhaled loxapine.
Patients will be randomly assigned to treatment to
avoid bias in terms of treatment allocation. The deliv-
ered treatment is necessarily open-label due to the dif-
ferent methods of administration. To avoid the issue of
rater bias, drug administration and clinical evaluation
will be carried out by different personnel, with the clin-
ical rater blinded to treatment allocation and the
randomization will be stratified by diagnosis to balance
the groups. Patients will be instructed not to tell the
treatment they receive.
Conclusion
In conclusion, the prompt stabilisation of patients with
schizophrenia or bipolar disorder presenting with acute
agitation has the potential to facilitate a patient-centered
management approach by maintaining the patient-
physician relationship and minimising the need for physical
or mechanical restraint or sedation [2, 3]. The PLACID
study will allow, for the first time, the direct comparison of
the timing of the onset of therapeutic effect of an IM anti-
psychotic, aripiprazole, and an inhaled antipsychotic, loxa-
pine, for the treatment of acute agitation in patients with
schizophrenia or bipolar disorder. The results of this trial
have the potential to change future treatment guidelines
and have a powerful impact on clinical practice.
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